BIOTECHNOLOGY IN INDIA – 2013 “BIOSPECTRUM-ABLE” SURVEY
According to the eleventh annual Indian Biotech Industry survey by Biospectrum-ABLE (Association of Biotechnology Led Enterprises), the Indian biotech industry grew by 15.1 % in 2012-13, increasing its revenues from 204.4 Billion INR (Indian Rupees) to 235.24 Billion INR (3.94 B US$ - exchange rate June 2013: 1 US$ approx. 60 INR).
Figure: Indian Biotech Industry 2002-13 (in Billion INR)
|
|
INDIAN BIOTECH SECTORS
Biotech companies covered by this survey are grouped according to the following sectors:
- BioPharma: includes vaccines, therapeutics and diagnostics
- BioAgri: includes genetically modified seeds, molecular markers and related products
- BioServices: includes contract research and manufacturing services (CRAMS) and clinical research services
- BioIndustrial: includes enzymes for food, leather and textiles, pharmaceuticals, detergents and energy applications
- BioInformatics: includes information technologies to develop tools for drug discovery, and informatics based services
|
MAJOR TRENDS
Based on a detailed questionnaire sent to over 200 companies, the annual survey captures the revenues – biotech products sales and service figures – or, if not available, relies on best estimates.
As in previous years, the Indian biotech industry is dominated by the BioPharma sector, which accounts for 63.5 % market share, followed by BioServices (18.5 %), BioAgri (13.6 %), BioIndustry (3.2 %) and BioInformatics (1.2 %). The differences in growth rates are significant, with BioPharma (17.7%) and BioServices (15.5%) leading the industry, followed by BioIndustrial (10.9%), BioInformatics (9.1%) and BioAgri (5.2%).
Figures for export (2,01 Billion US$) slightly exceeded domestic sales (1.93 Billion US$). Among exports, BioPharma (65 % of total exports) and BioServices (32 %) outweigh by far the other sectors with 1-2 % market share each.
The overall biotech industry registered on average 14.5 % annual growth over the last five years.
For details of this survey, please visit http://www.biospectrumindia.com, or http://www.ableindia.in
|
|
29.10.13 | DRUG DISCOVERY ALLIANCES IN INDIA - INDICATIONS, TARGETS AND NEW CHEMICAL ENTITIES
Global pharmaceutical and biotechnology companies have been building increasingly on the skills and services offered by Indian biotech companies. With the exception of generic press releases, however, very little has been published on the process and progress of drug discovery itself. In this review, we have analyzed recent patents, patent applications, and peer-reviewed publications of major research alliances, with the aim of highlighting their scientific output...
READ MORE
29.10.13 | HIGHLIGHTS FROM ASMC'13 - ADVANCES IN SYNTHETIC AND MEDICINAL CHEMISTRY - MAY 5-8, 2013, MOSCOW
Conference Report on ASMC'13 Moscow (May 5–8, 2013), highlighting new synthetic methodologies and expanding the drug discovery space from small to large molecules, including carbohydrates, novel protein scaffolds, dendrimers, and genes.
READ MORE
24.06.13 | BIOTECHNOLOGY IN INDIA – 2013 “BIOSPECTRUM-ABLE” SURVEY
According to the eleventh annual Indian Biotech Industry survey by Biospectrum-ABLE (Association of Biotechnology Led Enterprises), the Indian biotech industry grew by 15.1 % in 2012-13, increasing its revenues from 204.4 Billion INR (Indian Rupees) to 235.24 Billion INR (3.94 B US$).
READ MORE
11.06.13 | SAROGLITAZAR – FIRST NCE DISCOVERED AND DEVELOPED IN INDIA TO REACH THE MARKET
Zydus Cadila announced on June 5 2013 the approval by the Drug Controller General of India (DCGI) of Saroglitazar (ZYH1), or LipaglynTM. The drug has been approved for launch in India for the treatment of diabetic dyslipidemia or hypertriglyceridemia in patients with type II diabetes not controlled by statins alone.
READ MORE
25.02.13 | INNOVATIVE DRUG DISCOVERY IN INDIA – THE GROWING INDIAN R&D; PIPELINE
Ranbaxy’s recently launched Synriam, together with Glenmark’s (and US partner Salix Pharmaceuticals’) approval of Crofelemer are only the two first visible signs of India’s growing presence in innovative drug discovery and development...
READ MORE
30.07.12 | BIOTECHNOLOGY IN INDIA – 2012 “BIOSPECTRUM-ABLE” SURVEY
According to the tenth annual Indian Biotech Industry survey by Biospectrum-ABLE (Association of Biotechnology Led Enterprises), the Indian biotech industry passed the 4 Billion US$ mark in 2011-12...
READ MORE
03.01.12 | INDIAN DRUG DISCOVERY PIPELINE
In the late nineteen eighties, Indian pharma companies started in-house drug discovery activities, aiming at developing the country’s first home-made drug ...
READ MORE
03.01.12 | PHARMA AND BIOTECHNOLOGY ACTIVITIES IN INDIA
The Indian biotech industry has been booming over the past decade, growing from 0.5 Billion US$ in 2002-03 to more than 3.75 Billion US$ in 2010-11, and counting more than seven hundred players. ...
READ MORE
|
